REFERENCES
1. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80:2361-71.
2. Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2023;25:211-32.
3. Beermann J, Piccoli M, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96:1297-325.
4. Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575-9.
5. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15:261-71.
6. Han P, Li W, Lin C, et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature. 2014;514:102-6.
7. Sun J, Chen G, Jing Y, et al. LncRNA expression profile of human thoracic aortic dissection by high-throughput sequencing. Cell Physiol Biochem. 2018;46:1027-41.
8. Traxler D, Spannbauer A, Einzinger P, et al. Early elevation of systemic plasma clusterin after reperfused acute myocardial infarction in a preclinical porcine model of ischemic heart disease. Int J Mol Sci. 2020;21:4591.
9. Yang M, Zhang M, Li Z, et al. A landscape of long non-coding RNAs reveals the leading transcriptome alterations in murine aorta during aging. Genomics. 2023;115:110573.
10. Baulina N, Osmak G, Kiselev I, et al. NGS-identified circulating miR-375 as a potential regulating component of myocardial infarction associated network. J Mol Cell Cardiol. 2018;121:173-9.
11. Kim S, Lee S, Park J, Lee S, Kim H. Postmortem-derived exosomal microRNA 486-5p as potential biomarkers for ischemic heart disease diagnosis. Int J Mol Sci. 2024;25:9619.
12. Liao J, Wang J, Liu Y, Li J, Duan L. Transcriptome sequencing of lncRNA, miRNA, mRNA and interaction network constructing in coronary heart disease. BMC Med Genomics. 2019;12:124.
13. Ramachandran V, Bhagavatheeswaran S, Shanmugam S, et al. Deep sequencing unveils altered cardiac miRNome in congenital heart disease. Mol Genet Genomics. 2022;297:1123-39.
14. Niu X, Liang G, Chen S, et al. MicroRNA profiling reveals novel biomarkers for cardiovascular and psychological health in plateau psycho CVD. Sci Rep. 2025;15:12488.
15. Van Rooij E, Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol Med. 2014;6:851-64.
16. Xu J, Qian B, Wang F, et al. Global profile of tRNA-derived small rnas in pathological cardiac hypertrophy plasma and identification of tRF-21-NB8PLML3E as a new hypertrophy marker. Diagnostics. 2023;13:2065.
17. Zhao L, Peng Y, Su P. Expression profiles and functional analysis of tRNA-derived small RNAs in epicardial adipose tissue of patients with heart failure. Ann Med. 2023;55:2267981.
18. Rajagopalan V, Chakraborty S, Lin R. Novel transcriptomic interactomes of noncoding RNAs in the heart under altered thyroid hormonal states. Int J Mol Sci. 2023;24:6560.
19. Jain G, Stuendl A, Rao P, et al. A combined miRNA-piRNA signature to detect Alzheimer’s disease. Transl Psychiatry. 2019;9:250.
20. Gu X, Wang C, Deng H, et al. Exosomal piRNA profiling revealed unique circulating piRNA signatures of cholangiocarcinoma and gallbladder carcinoma. Acta Biochim Biophys Sin. 2020;52:475-84.
21. Huang X, Yuan T, Tschannen M, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. 2013;14:319.
22. Ogawa Y, Taketomi Y, Murakami M, Tsujimoto M, Yanoshita R. Small RNA Transcriptomes of two types of exosomes in human whole saliva determined by next generation sequencing. Biol Pharm Bull. 2013;36:66-75.
23. Yuan T, Huang X, Woodcock M, et al. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep. 2016;6:19413.
24. Jouravleva K, Zamore PD. A guide to the biogenesis and functions of endogenous small non-coding RNAs in animals. Nat Rev Mol Cell Biol. 2025;26:347-70.
25. Gao F, Wang F, Cao H, Chen Y, Diao Y, Kapranov P. Evidence for existence of multiple functional human small RNAs derived from transcripts of protein-coding genes. Int J Mol Sci. 2023;24:4163.
26. Wong L, Tsang YS, Kenny R, Lyburn M, Mcmahon LP. MiR-423-5p as Optimal Endogenous Control for Quantification of Circulating MicroRNAs in Patients With CKD. Kidney Int Rep. 2023;8:2150-2.
27. Chen L, Kim VN. Small and long non-coding RNAs: past, present, and future. Cell. 2024;187:6451-85.
28. Caporali A, Anwar M, Devaux Y, et al. Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease. Nat Rev Cardiol. 2024;21:556-73.
29. Riffo-campos AL, Perez-hernandez J, Martinez-arroyo O, et al. Biofluid specificity of long non-coding RNA profile in hypertension: relevance of exosomal fraction. Int J Mol Sci. 2022;23:5199.
30. Wang Y, Trinh MP, Zheng Y, Guo K, Jimenez LA, Zhong W. Analysis of circulating non-coding RNAs in a non-invasive and cost-effective manner. Trends Analyt Chem. 2019;117:242-62.
31. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203-22.
32. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630-43.
33. Geng B, Zhang Z, Xu Y, et al. The landscape of noncoding RNAs in cardiovascularaging and disease. Scierxiv 2025;2025060231.
34. Yuan J, Chen H, Ge D, et al. Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting smad7. Cell Physiol Biochem. 2017;42:2207-19.
35. Fitzsimons S, Oggero S, Bruen R, et al. microRNA-155 is decreased during atherosclerosis regression and is increased in urinary extracellular vesicles during atherosclerosis progression. Front. Immunol. 2020;11:576516.
36. Ohta M, Kihara T, Toriuchi K, et al. IL-6 promotes cell adhesion in human endothelial cells via microRNA-126-3p suppression. Exp Cell Res. 2020;393:112094.
37. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008;22:3242-54.
38. Michalik KM, You X, Manavski Y, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114:1389-97.
39. Zhou J. LncRNA MIAT promotes hypoxia‐induced H9C2 cell pyroptosis via binding to SF1 to inhibit CGRP transcription. Exp Physiol. 2021;107:58-67.
40. Wang K, Long B, Liu F, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. 2016;37:2602-11.
41. Fang J, Pan Z, Guo X. Research advance of ANRIL on atherosclerosis by regulating cell proliferation and apoptosis. J. Zhejiang Univ. (Med Sci.). 2020;49:113-7.
42. Micheletti R, Plaisance I, Abraham BJ, et al. The long noncoding RNA wisper controls cardiac fibrosis and remodeling. Sci Transl Med. 2017;9:eaai9118.
43. Boos F, Oo JA, Warwick T, et al. The endothelial-enriched lncRNA LINC00607 mediates angiogenic function. Basic Res Cardiol. 2023;118:5.
44. Sriram K, Luo Y, Yuan D, et al. Vascular regulation by super enhancer-derived LINC00607. Front. Cardiovasc. Med. 2022;9:881916.
45. Surina, Fontanella RA, Scisciola L, Marfella R, Paolisso G, Barbieri M. miR-21 in human cardiomyopathies. Front. Cardiovasc. Med. 2021;8:767064.
46. Ma YL, Ma ZJ, Wang M, Liao MY, Yao R, Liao YH. MicroRNA-155 induces differentiation of RAW264.7 cells into dendritic-like cells. Int J Clin Exp Pathol. 2015;8:14050-62.
47. Wu XY, Fan WD, Fang R, Wu GF. Regulation of microRNA-155 in endothelial inflammation by targeting nuclear factor (NF)-κB P65. J Cell Biochem. 2014;115:1928-36.
48. Xiao Q, Wang D, Sheng Y, Huang J, Ha X. MicroRNA-126 regulates thrombosis through endothelial progenitor cells. DNA Cell Biol. 2023;42:315-21.
49. Toraih EA, El-wazir A, Alghamdi SA, et al. Association of long non-coding RNA MIAT and MALAT1 expression profiles in peripheral blood of coronary artery disease patients with previous cardiac events. Genet Mol Biol. 2019;42:509-18.
50. Akan G, Nyawawa E, Nyangasa B, et al. Severity of coronary artery disease is associated with diminished circANRIL expression: A possible blood based transcriptional biomarker in East Africa. J Cell Mol Med. 2023;28:e18093.
51. Van Ingen E, Engbers PA, Woudenberg T, et al. C/D box snoRNA SNORD113-6 guides 2’-O-methylation and protects against site-specific fragmentation of tRNALeu(TAA) in vascular remodeling. Mol Ther Nucleic Acids. 2022;30:162-72.
52. van Ingen E, van den Homberg DAL, van der Bent ML, et al. C/D box snoRNA SNORD113-6/AF357425 plays a dual role in integrin signalling and arterial fibroblast function via pre-mRNA processing and 2’O-ribose methylation. Hum Mol Genet. 2022;31:1051-66.
53. Will CL, Luhrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol. 2010;3:a003707.
54. Cao J, Wei Z, Nie Y, Chen H. Therapeutic potential of alternative splicing in cardiovascular diseases. eBioMedicine. 2024;101:104995.
55. Yang F, Xi R. Silencing transposable elements in the drosophila germline. Cell Mol Life Sci. 2016;74:435-48.
56. Sokolova OA, Iakushev E, Stoliarenko AD, Mikhaleva EA, Gvozdev VA, Klenov MS. The interplay of transposon silencing genes in the drosophila melanogaster germline. Mol Biol. (Mosk.). 2011;45:633-41.
57. Anzelon TA, Chowdhury S, Hughes SM, Xiao Y, Lander GC, Macrae IJ. Structural basis for piRNA targeting. Nature. 2021;597:285-9.
58. Wang J, Dong P, Xu X, et al. Identification of tRNA-derived fragments and their potential roles in atherosclerosis. Curr Med Sci. 2021;41:712-21.
59. Soares AR, Santos M. Discovery and function of transfer RNA‐derived fragments and their role in disease. Wiley Interdiscip Rev RNA. 2017;8:e1423.
60. Fu X, He X, Yang Y, et al. Identification of transfer RNA-derived fragments and their potential roles in aortic dissection. Genomics. 2021;113:3039-49.
61. Kim HK, Yeom J, Kay MA. Transfer RNA-derived small RNAs: another layer of gene regulation and novel targets for disease therapeutics. Mol Ther. 2020;28:2340-57.
62. Zhou M, He X, Zhang J, Mei C, Zhong B, Ou C. tRNA-derived small RNAs in human cancers: roles, mechanisms, and clinical application. Mol Cancer. 2024;23:76.
63. Rashad S, Al-mesitef S, Mousa A, et al. Translational response to mitochondrial stresses is orchestrated by tRNA modifications. bioRxiv 2024.
64. Brogli R, Cristodero M, Schneider A, Polacek N. A ribosome-bound tRNA half stimulates mitochondrial translation during stress recovery in trypanosoma brucei. Cell Rep. 2023;42:113112.
65. Zhang L, Liu J, Hou Y. Classification, function, and advances in tsRNA in non-neoplastic diseases. Cell Death Dis. 2023;14:748.
66. Cao J, Cowan DB, Wang D. tRNA-derived small RNAs and their potential roles in cardiac hypertrophy. Front. Pharmacol. 2020;11:572941.
67. Zuo J, Zhang Z, Li M, et al. The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role. Mol Cancer. 2022;21:30.
68. He S, Huang B, Xu F, et al. Functions and application of circRNAs in vascular aging and aging-related vascular diseases. J Nanobiotechnol. 2025;23:216.
69. Wang Z, Zhang X, Li W, Yang B. Decoding noncoding RNAs in regulating cardiovascular aging and age-related conditions: the emerging landscape. Sci. China Life Sci. 2025;69:353-83.
70. Jusic A, Thomas PB, Wettinger SB, et al. Noncoding RNAs in age-related cardiovascular diseases. Ageing Res Rev. 2022;77:1016.
71. Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun. 2010;398:735-40.
72. Menghini R, Casagrande V, Cardellini M, et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation. 2009;120:1524-32.
73. Hofmann P, Sommer J, Theodorou K, et al. Long non-coding RNA H19 regulates endothelial cell aging via inhibition of STAT3 signalling. Cardiovasc Res. 2019;115:230-42.
74. Boon RA, Hofmann P, Michalik KM, et al. Long noncoding RNA Meg3 controls endothelial cell aging and function: implications for regenerative angiogenesis. J Am Coll Cardiol. 2016;68:2589-91.
75. Das S, Bedja D, Campbell N, et al. miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS ONE. 2014;9:e96820.
76. Li D, Mao C, Zhou E, et al. MicroRNA-21 Mediates a positive feedback on angiotensin II-induced myofibroblast transformation. J Inflamm Res. 2020;13:1007-20.
77. Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570-3.
78. Najafi-shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566-9.
79. Dávalos A, Fernández-hernando C. From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacol Res. 2013;75:60-72.
80. Correction to: LincRNA-p21 Regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 2019;139.
81. Razeghian-jahromi I, Karimi Akhormeh A, Zibaeenezhad MJ. The role of ANRIL in atherosclerosis. Dis Markers. 2022;2022:1-10.
82. Chi J, Li J, Jia J, Zhang T, Liu X, Yi L. Long non-coding RNA ANRIL in gene regulation and its duality in atherosclerosis. CURR MED SCI. 2017;37:816-22.
83. Sothivelr V, Hasan MY, Mohd Saffian S, Zainalabidin S, Ugusman A, Mahadi MK. Revisiting miRNA-21 as a therapeutic strategy for myocardial infarction: a systematic review. J Cardiovasc Pharmacol. 2022;80:393-406.
84. Wu Y, Zhang K, Liu R, et al. MicroRNA-21-3p accelerates diabetic wound healing in mice by downregulating SPRY1. Aging. 2020;12:15436-45.
85. Gui Y, Li D, Chen J, et al. Soluble epoxide hydrolase inhibitors, t-AUCB, downregulated miR-133 in a mouse model of myocardial infarction. Lipids Health Dis. 2018;17:129.
86. Al-muhtaresh HA, Salem AH, Al-kafaji G. Upregulation of circulating cardiomyocyte-enriched miR-1 and miR-133 associate with the risk of coronary artery disease in type 2 diabetes patients and serve as potential biomarkers. J Cardiovasc Transl Res. 2019;12:347-57.
87. Qu X, Du Y, Shu Y, et al. MIAT Is a Pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium. Sci Rep. 2017;7:42657.
88. Mohammadi A, Balizadeh Karami AR, Dehghan Mashtani V, et al. Evaluation of oxidative stress, apoptosis, and expression of microRNA-208a and microRNA-1 in cardiovascular patients. Rep Biochem Mol Biol. 2021;10:183-96.
89. Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). J Mol Cell Cardiol. 2016;94:107-21.
90. Boštjančič E, Zidar N, Štajer D, Glavač D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology. 2010;115:163-9.
91. Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124:1537-47.
92. Kontaraki JE, Marketou ME, Kochiadakis GE, et al. The long non-coding RNAs MHRT,FENDRR and CARMEN, their expression levels in peripheral blood mononuclear cells in patients with essential hypertension and their relation to heart hypertrophy. Clin Exp Pharmacol Physiol. 2018;45:1213-7.
93. Liao C, Gui Y, Guo Y, Xu D. The regulatory function of microRNA-1 in arrhythmias. Mol Biosyst. 2016;12:328-33.
94. Sun L, Sun S, Zeng S, Li Y, Pan W, Zhang Z. Expression of circulating microRNA-1 and microRNA-133 in pediatric patients with tachycardia. Mol Med Rep. 2015;11:4039-46.
95. Chen L, Sampson KJ, Kass RS. Cardiac delayed rectifier potassium channels in health and disease. Card Electrophysiol Clin. 2016;8:307-22.
96. Shimizu W, Horie M. Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels. Circ Res. 2011;109:97-109.
97. Cao WJ, Rosenblat JD, Roth NC, et al. Therapeutic angiogenesis by ultrasound-mediated microRNA-126-3p delivery. Arterioscler Thromb Vasc Biol. 2015;35:2401-11.
98. Zhang Y, Xu Y, Zhou K, Kao G, Xiao J. MicroRNA‑126 and VEGF enhance the function of endothelial progenitor cells in acute myocardial infarction. Exp Ther Med. 2021;23:142.
99. Li D, Zhang C, Li J, et al. Long non-coding RNA MALAT1 promotes cardiac remodeling in hypertensive rats by inhibiting the transcription of MyoD. Aging. 2019;11:8792-809.
100. Liu H, Zhang Z, Xiong W, et al. Long non‐coding RNA MALAT1 mediates hypoxia‐induced pro‐survival autophagy of endometrial stromal cells in endometriosis. J Cell Mol Med. 2018;23:439-52.
101. Zhou Q, Boeckel JN, Yao J, et al. Diagnosis of acute myocardial infarction using a combination of circulating circular RNA cZNF292 and clinical information based on machine learning. MedComm. 2023;4:e299.
102. Zhang T, Huang W. Angiogenic circular RNAs: A new landscape in cardiovascular diseases. Microvasc Res. 2020;129:103983.
103. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem. 2006;281:18277-84.
104. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16:1590-8.
105. Courboulin A, Paulin R, Giguère NJ, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208:535-48.
106. Gou D, Ramchandran R, Peng X, et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am J Physiol Lung Cell Mol Physiol. 2012;303:L682-91.
107. Fomison-nurse I, Saw EEL, Gandhi S, et al. Diabetes induces the activation of pro-ageing miR-34a in the heart, but has differential effects on cardiomyocytes and cardiac progenitor cells. Cell Death Differ. 2018;25:1336-49.
108. Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW, Chakrabarti S. Cardiac miR‐133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med. 2014;18:415-21.
109. Gao L, Wang X, Guo S, et al. LncRNA HOTAIR functions as a competing endogenous RNA to upregulate SIRT1 by sponging miR‐34a in diabetic cardiomyopathy. J Cell Physiol. 2018;234:4944-58.
110. Kankuri E. Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction. Mol Ther Nucleic Acids. 2023;32:318-21.
111. Zhan J, Jin K, Xie R, et al. AGO2 protects against diabetic cardiomyopathy by activating mitochondrial gene translation. Circulation. 2024;149:1102-20.
112. Gedikbasi A, Adas G, Isiksacan N, et al. The effect of host miRNAs on prognosis in COVID-19: miRNA-155 may promote severity via targeting suppressor of cytokine signaling 1 (SOCS1) gene. Genes. 2022;13:1146.
113. Adel RM, Helal H, Ahmed Fouad M, Sobhy Abd-elhalem S. Regulation of miRNA-155-5p ameliorates NETosis in pulmonary fibrosis rat model via inhibiting its target cytokines IL-1β, TNF-α and TGF-β1. Int Immunopharmacol. 2024;127:111456.
114. Zhang L, Ouyang P, He G, et al. Exosomes from microRNA‐126 overexpressing mesenchymal stem cells promote angiogenesis by targeting the PIK3R2‐mediated PI3K/Akt signalling pathway. J Cell Mol Med. 2020;25:2148-62.
115. Ge Y, Wang Q, Qin X, et al. Tetrahedral framework nucleic acids connected with microRNA-126 mimics for applications in vascular inflammation, remodeling, and homeostasis. ACS Appl Mater Interfaces. 2022;14:19091-103.
116. Xue Y, Li Z, Liu W, Shan J, Wang L, Su Q. Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension. Aging. 2019;11:5192-205.
117. Zhang Y, Guan X, Wang H, Wang Y, Yue D, Chen R. Long non‑coding RNA metastasis‑associated lung adenocarcinoma transcript 1 regulates renal cancer cell migration via cofilin‑1. Oncol Lett. 2020.
118. Chen Y, Zhou J, Wei Z, et al. Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis. Front Pharmacol. 2022;13:940768.
119. Hu Y, Cao H, Sheng J, et al. Functional role of circRNA CHRC through miR-431-5p/KLF15 signaling axis in the progression of heart failure. J Genet Genomics. 2024;51:844-54.
120. Yang M, Wang H, Han S, et al. Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy. Aging. 2020;12:2530-44.
121. Pan S, Zhao X, Shao C, et al. STIM1 promotes angiogenesis by reducing exosomal miR-145 in breast cancer MDA-MB-231 cells. Cell Death Dis. 2021;12:38.
122. Zhou H, Zhou J, Teng H, Yang H, Qiu J, Li X. MiR-145 enriched exosomes derived from bone marrow-derived mesenchymal stem cells protects against cerebral ischemia-reperfusion injury through downregulation of FOXO1. Biochem Biophys Res Commun. 2022;632:92-9.
123. Gao W, Zhang Y, Yuan L, Huang F, Wang YS. Long non‐coding RNA H19‐overexpressing exosomes ameliorate UVB‐induced photoaging by upregulating SIRT1 via sponging miR‐138. Photochem Photobiol. 2023;99:1456-67.
124. Wang J, Cao B, Sun R, Chen Y, Feng J. RETRACTED: Exosome-transported long non-coding ribonucleic acid H19 induces blood-brain barrier disruption in cerebral ischemic stroke via the H19/micro ribonucleic acid-18a/vascular endothelial growth factor axis. Neuroscience. 2022;500:41-51.
125. Hashemi M, Moosavi MS, Abed HM, et al. Long non-coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy. Pharmacol Res. 2022;184:106418.
126. Arderiu G, Peña E, Aledo R, et al. MicroRNA-145 regulates the differentiation of adipose stem cells toward microvascular endothelial cells and promotes angiogenesis. Circ Res. 2019;125:74-89.
127. Liu X, Zhong L, Jiang W, Wen D. Repression of circRNA_000684 inhibits malignant phenotypes of pancreatic ductal adenocarcinoma cells via miR-145-mediated KLF5. Pancreatology. 2021;21:406-17.
128. Wang J, Lin Y, Jiang DH, Yang X, He XG. CircRNA ZNF609 promotes angiogenesis in nasopharyngeal carcinoma by regulating miR‐145/STMN1 axis. Kaohsiung J Med Sci. 2021;37:686-98.
129. Legnini I, Di Timoteo G, Rossi F, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. 2017;66:22-37.e9.
130. Ye J, Guo R, Shi Y, Qi F, Guo C, Yang L. miR-155 regulated inflammation response by the SOCS1-STAT3-PDCD4 axis in atherogenesis. Mediators Inflamm. 2016;2016:1-14.
131. Billeter AT, Hellmann J, Roberts H, et al. MicroRNA‐155 potentiates the inflammatory response in hypothermia by suppressing IL‐10 production. FASEB J. 2014;28:5322-36.
132. Pathak S, Grillo AR, Scarpa M, et al. MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis. Exp Mol Med. 2015;47:e164.
133. Liu E, Lv L, Zhan Y, et al. METTL3/N6‐methyladenosine/ miR‐21‐5p promotes obstructive renal fibrosis by regulating inflammation through SPRY1/ERK/NF‐κB pathway activation. J Cell Mol Med. 2021;25:7660-74.
134. Kong C, Lyu D, He C, Li R, Lu Q. Dioscin elevates lncRNA MANTIS in therapeutic angiogenesis for heart diseases. Aging Cell. 2021;20:e13392.
135. Leisegang MS, Fork C, Josipovic I, et al. Long noncoding RNA MANTIS facilitates endothelial angiogenic function. Circulation. 2017;136:65-79.
136. Gareev I, Kudriashov V, Sufianov A, et al. The role of long non-coding RNA ANRIL in the development of atherosclerosis. Noncoding RNA Res. 2022;7:212-6.
137. Chandy M, Ishida M, Shikatani EA, et al. c-Myb regulates transcriptional activation of miR-143/145 in vascular smooth muscle cells. PLoS One. 2018;13:e0202778.
138. Lan S, Albinsson S. Regulation of IRS-1, insulin signaling and glucose uptake by miR-143/145 in vascular smooth muscle cells. Biochem Biophys Res Commun. 2020;529:119-25.
139. Werner JH, Rosenberg JH, Um JY, Moulton MJ, Agrawal DK. Molecular discoveries and treatment strategies by direct reprogramming in cardiac regeneration. Transl Res. 2019;203:73-87.
140. Li X, Ni L, Wang W, Zong L, Yao B. LncRNA fendrr inhibits hypoxia/reoxygenation-induced cardiomyocyte apoptosis by downregulating p53 expression. J Pharm Pharmacol. 2020;72:1211-20.
141. Zhou J, Qiu C, Fan Z, Liu T, Liu T. Circular RNAs in stem cell differentiation: a sponge-like role for miRNAs. Int J Med Sci. 2021;18:2438-48.
142. Wang F, Li X, Li Z, Wang S, Fan J. Functions of circular RNAs in regulating adipogenesis of mesenchymal stem cells. Stem Cells International. 2020;2020:1-12.
143. Zhang L, Tang M, Diao H, Xiong L, Yang X, Xing S. LncRNA-encoded peptides: unveiling their significance in cardiovascular physiology and pathology-current research insights. Cardiovasc Res. 2023;119:2165-78.
144. Li F, Du WW, Li X, et al. A new protein isoform encoded by human circular RNA circSLC8a1 contributes to cardiac remodelling. Cardiovasc Res. 2025;121:882-99.
145. Hu D, Lin Y, Huang H, et al. CircZBTB44-encoded peptide ZBTB44-342aa alleviates aortic valve calcification via cGAS-STING inhibition. Circ Res. 2026;138.
146. Liu Y, He M, Yuan Y, et al. Neutrophil-membrane-coated biomineralized metal-organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing. ACS Nano. 2023;17:7721-32.
147. Kmiotek‐wasylewska K, Łabędź‐masłowska A, Bobis‐wozowicz S, et al. Induced pluripotent stem cell‐derived extracellular vesicles enriched withmiR‐126 induce proangiogenic properties and promote repair of ischemic tissue. FASEB J. 2024;38:e23415.
148. Gao S, Gao H, Dai L, et al. miR-126 regulates angiogenesis in myocardial ischemia by targeting HIF-1α. Exp Cell Res. 2021;409:112925.
149. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430-40.
150. Boštjančič E, Brandner T, Zidar N, Glavač D, Štajer D. Down-regulation of miR-133a/b in patients with myocardial infarction correlates with the presence of ventricular fibrillation. Biomed Pharmacother. 2018;99:65-71.
151. Xin Y, Yang C, Han Z. Circulating miR-499 as a potential biomarker for acute myocardial infarction. Ann. Transl. Med. 2016;4:135.
152. Adachi T, Nakanishi M, Otsuka Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010;56:1183-5.
153. Tan J, Ma X, Wang G, Jiang C, Gong H, Liu H. LncRNA MIAT knockdown alleviates oxygen-glucose deprivation‑induced cardiomyocyte injury by regulating JAK2/STAT3 pathway via miR-181a-5p. J Cardiol. 2021;78:586-97.
154. Hu K, Yan T, Cao K, et al. A tRNA-derived fragment of ginseng protects heart against ischemia/reperfusion injury via targeting the lncRNA MIAT/VEGFA pathway. Mol Ther Nucleic Acids. 2022;29:672-88.
155. Holdt LM, Stahringer A, Sass K, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016;7:12429.
156. Shi P, Ji H, Zhang H, Yang J, Guo R, Wang J. circANRIL reduces vascular endothelial injury, oxidative stress and inflammation in rats with coronary atherosclerosis. Exp Ther Med. 2020;20:2245-51.
157. Qin Q, Zheng P, Tu R, Huang J, Cao X. Integrated bioinformatics analysis for the identification of hub genes and signaling pathways related to circANRIL. PeerJ. 2022;10:e13135.
158. Adams D, Gonzalez-duarte A, O’riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11-21.
159. Nair JK, Willoughby JLS, Chan A, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958-61.
160. Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109-18.
161. Zhou XL, Xu H, Liu ZB, Wu QC, Zhu RR, Liu JC. miR‐21 promotes cardiac fibroblast‐to‐myofibroblast transformation and myocardial fibrosis by targeting Jagged1. J Cell Mol Med. 2018;22:3816-24.
162. Zhou Z, Schober A, Nazari-jahantigh M. Dicer promotes endothelial recovery and limits lesion formation after vascular injury through miR-126-5p. Int J Cardiol. 2018;273:199-202.
163. Batkai S, Genschel C, Viereck J, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021;42:192-201.
164. Täubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178-88.
165. Bauersachs J, Solomon SD, Anker SD, et al. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial. Eur J Heart Fail. 2024;26:674-82.
166. Nie T, Heo Y, Shirley M. Vutrisiran: a review in polyneuropathy of hereditary transthyretin-mediated amyloidosis. Drugs. 2023;83:1425-32.
167. Garcia-Pavia P, Grogan M, Kale P, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024;26:397-4.
168. Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2025;392:33-44.
169. Griffiths-jones S. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140-4.
170. Volders P, Anckaert J, Verheggen K, et al. LNCipedia 5: towards a reference set of human long non-coding RNAs. Nucleic Acids Res. 2019;47:D135-9.
